US OptionsDetailed Quotes

CRBU241115P500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 5 09:30 ET

0.00High0.00Low

Caribou Biosciences Stock Discussion

Stock_Drift

Sep 25 08:16

$Caribou Biosciences (CRBU.US)$

FattyChick

Sep 13 12:24

Next 3 stocks keeping an eye on.

$Caribou Biosciences (CRBU.US)$
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.

Trytosaveabit

Sep 3 07:01

News

$Caribou Biosciences (CRBU.US)$ Reuters· just
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml

Jaguar8

Jun 2 20:24

NEWS

$Caribou Biosciences (CRBU.US)$
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...

Trytosaveabit

Apr 16 05:31

Hmm?

$Caribou Biosciences (CRBU.US)$ Got a inverted hammer on the daily! Its wick actually broke above the downtrend continuation wedge! Its Really OS RSI 7 = 14.58! RSI 14 = 24.96! MACD Looks as if its fixing to GC? So lets just see how this turns out? Just thinking outloud

Trytosaveabit

Apr 4 15:07

Update

$Caribou Biosciences (CRBU.US)$ Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...

Moomoo AI

Feb 15 04:27

Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.

There's Reason For Concern Over Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Massive 25% Price Jump

Moomoo AI

Jan 4 08:17

Caribou Biosciences' revenue growth is promising but rising cash burn rate could concern investors. Raising more capital may result in shareholder dilution, making the situation risky.

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Aspiring_Millionaire

Dec 28, 2023 12:17

$Caribou Biosciences (CRBU.US)$ this stock 🥲

Trytosaveabit

Dec 13, 2023 03:31

Update

$Caribou Biosciences (CRBU.US)$ Caribou Biosciences (CRBU) said late Tuesday it has reached alignment with the US Food and Drug Administration with respect to the trial design of a planned phase 3 study of CB-010 for the treatment of patients with second-line relapsed or refractory large B cell lymphoma.
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...

No comment yet